脂蛋白(a)、低密度脂蛋白胆固醇及其在阿利西尤单抗治疗下变化与新发糖尿病风险:ODYSSEY OUTCOMES随机试验的事后分析
该事后分析纳入8,107例近期急性冠脉综合征且基线无糖尿病的患者,随机接受阿利西尤单抗或安慰剂,中位随访2.4年。基线脂蛋白(a)较低和胰岛素或HOMA-IR较高独立预测782例新发糖尿病,基线LDL-C不预测新发糖尿病。阿利西尤单抗降低脂蛋白(a)和LDL-C但不影响胰岛素或新发糖尿病风险(OR 0.998,95%CI 0.860-1.158);在阿利西尤单抗治疗中,脂蛋白(a)降低与新发糖尿病风险升高独立相关,LDL-C降低与新发糖尿病风险降低独立相关。
要点
- 基线脂蛋白(a)较低、胰岛素或HOMA-IR较高独立预测新发糖尿病,基线LDL-C不预测新发糖尿病。
- 阿利西尤单抗降低脂蛋白(a)和LDL-C,但不影响胰岛素水平或新发糖尿病风险(OR 0.998,95%CI 0.860-1.158)。
- 阿利西尤单抗治疗中脂蛋白(a)降低与新发糖尿病风险升高相关,LDL-C降低与新发糖尿病风险降低相关,净效应为零。
核心结论
- 基线脂蛋白(a)与新发糖尿病风险呈负相关。
- 阿利西尤单抗诱导的脂蛋白(a)降低和LDL-C降低分别与新发糖尿病风险升高和降低相关,但对新发糖尿病无净效应。
- 正在进行的试验将确定更大程度和更长时间的脂蛋白(a)降低对新发糖尿病的影响。
研究设计与样本
- ODYSSEY OUTCOMES试验(NCT01663402)的事后分析。
- 纳入8,107例近期急性冠脉综合征、接受优化他汀治疗且基线无糖尿病的患者,随机分配至阿利西尤单抗或安慰剂组,中位随访2.4年。
- 采用logistic回归模型估计样条曲线。
主要发现
- 基线脂蛋白(a)较低和基线胰岛素或HOMA-IR较高独立预测782例新发糖尿病;基线LDL-C不预测新发糖尿病。
- 阿利西尤单抗降低脂蛋白(a)和LDL-C,但不影响胰岛素或新发糖尿病风险(与安慰剂相比OR 0.998;95%CI 0.860-1.158)。
- 在阿利西尤单抗治疗中,脂蛋白(a)降低25%和50%时新发糖尿病OR分别为1.12(95%CI 1.01-1.23)和1.24(95%CI 1.02-1.52)。
- 在阿利西尤单抗治疗中,LDL-C降低25%和50%时新发糖尿病OR分别为0.88(95%CI 0.80-0.97)和0.77(95%CI 0.64-0.94)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Previous genetic and clinical analyses have associated lower lipoprotein(a) and LDL cholesterol (LDL-C) with greater risk of new-onset type 2 diabetes (NOD). However, PCSK9 inhibitors such as alirocumab lower both lipoprotein(a) and LDL-C without effect on NOD. RESEARCH DESIGN AND METHODS: In a post hoc analysis of the ODYSSEY OUTCOMES trial (NCT01663402), we examined the joint prediction of NOD by baseline lipoprotein(a), LDL-C, and insulin (or HOMA-insulin resistance [HOMA-IR]) and their changes with alirocumab treatment. Analyses included 8,107 patients with recent acute coronary syndrome on optimized statin therapy, without diabetes at baseline, assigned to alirocumab or placebo with median follow-up 2.4 years. Splines were estimated from logistic regression models. RESULTS: Lower baseline lipoprotein(a) and higher baseline insulin or HOMA-IR independently predicted 782 cases of NOD; baseline LDL-C did not predict NOD. Alirocumab reduced lipoprotein(a) and LDL-C without affecting insulin or NOD risk (odds ratio [OR] vs. placebo 0.998; 95% CI 0.860-1.158). However, in logistic regression, decreased lipoprotein(a) and LDL-C on alirocumab were independent, opposite predictors of NOD. OR for NOD for 25% and 50% lipoprotein(a) reductions on alirocumab were 1.12 (95% CI 1.01-1.23) and 1.24 (1.02-1.52). OR for NOD for 25% and 50% LDL-C reductions on alirocumab were 0.88 (95% CI 0.80-0.97) and 0.77 (0.64-0.94). CONCLUSIONS: Baseline lipoprotein(a) was inversely associated with risk of NOD. Alirocumab-induced reductions of lipoprotein(a) and LDL-C were associated with increased and decreased risk of NOD, respectively, without net effect on NOD. Ongoing trials will determine the impact of larger and longer lipoprotein(a) reductions on NOD.
引用
- Schwartz GG, Szarek M, Jukema JW, et al. Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial. Diabetes Care. 2025. PMID: 39913634. doi:10.2337/dc24-2110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。